Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease
Eosinophil reduction was identified as a marker for early response to ustekinumab in both UC and CD, but not adalimumab. No difference was observed among UC patients treated with vedolizumab either. Targeting the IL-12/IL-23 pathway may be more effective in managing eosinophil-associated inflammation in IBD.
Authors
- Emily C L Wong (ORCID: https://orcid.org/0000-0001-9472-201X)
- Walter Reinisch (ORCID: https://orcid.org/0000-0002-2088-091X)
- John K. Marshall (ORCID: https://orcid.org/0000-0002-0523-9032)
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
Institutions
- Northwestern University (US)
- Western University (CA)
- Northwestern University (PH)
- Institut de Recherche en Santé Digestive (FR)
- Northwestern Medicine (US)
- Medical University of Vienna (AT)
- McMaster University (CA)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf006
- Citations
- 5
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 10.03